The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats

Jun Li, Randy S. Daughters, Christopher Bullis, Rimon Bengiamin, Mark W. Stucky, John Brennan, Donald A. Simone

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Although it is well known that cannabinoids produce antinociception in acute pain models, there is less information on the ability of cannabinoids to alleviate hyperalgesia. In the present study, we determined whether cannabinoids attenuated the development of hyperalgesia produced by intraplantar injection of capsaicin in rats. In normal, untreated animals, intraplantar injection of 10 μg capsaicin produces nocifensive behavior (elevation of the injected paw) suggestive of pain, an increase in the frequency of withdrawal from punctate mechanical stimuli applied to the paw (mechanical hyperalgesia) and a decrease in the latency of withdrawal from noxious heat (heat hyperalgesia). Separate groups of animals were pretreated intravenously with vehicle, the cannabinoid receptor agonist WIN 55,212-2 at doses of 1,10 100 or 200 μg/kg, or the enantiomer WIN 55,212-3 (100 μg/kg) 5 min before intraplantar injection of capsaicin into one paw. The duration of nocifensive behavior was measured during the first 5 min after capsaicin injection. Withdrawal responses to mechanical and heat stimuli applied to the plantar surface of both hindpaws were measured before and at 5 and 30 min after capsaicin. Pretreatment with WIN 55,212-2 produced a dose-dependent decrease in nocifensive behavior and in hyperalgesia to mechanical and heat stimuli produced by capsaicin, as compared with vehicle pretreatment. Doses of 100 and 200 μg/kg WIN 55,212-2 completely blocked the development of hyperalgesia to mechanical and heat stimuli without altering withdrawal responses on the contralateral control paw. Furthermore, these doses of WIN 55,212-2 had no effect on basal withdrawal responses to heat in animals that did not receive capsaicin. The inactive enantiomer WIN 55,212-3 did not alter the development of capsaicin-evoked pain or hyperalgesia. These data suggest that low doses of cannabinoids, which do not produce analgesia or impair motor function, attenuate chemogenic pain and possess antihyperalgesic properties. Copyright (C) 1999 International Association for the Study of Pain.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
Issue number1-2
StatePublished - May 1 1999

Bibliographical note

Funding Information:
This work was supported in part by grants from the National Institutes of Health (NS31223) to D.A.S. and from the Department of Anesthesiology, University of Minnesota, to M.W.S. Jun Li was supported by the Minnesota Pain Research Training Grant (DE07288). Chris Bullis was supported by a Lund Summer Research Fellowship through Hamline University. The authors thank Dr. Paul Thuras for assistance with statistical analyses and Dr. Virginia Seybold for critically reading an early version of the manuscript.


  • CB1 receptor
  • Cannabinboids
  • Mechanical hyperalgesia
  • Pain
  • Thermal hyperalgesia


Dive into the research topics of 'The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats'. Together they form a unique fingerprint.

Cite this